NewsRoom

NEWS RELEASES

2018

- Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

- Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting

- Salix Resolves Legacy SEC Investigation With No Penalty

- Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

- Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation

- Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies

- US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA (lofexidine) At 2018 PAINWeek Conference

- US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA (lofexidine) 0.18 Mg Tablets

- Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

- Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA (lofexidine)

- Salix To Highlight New Clinical Data During Digestive Disease Week

- Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies

- Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection

- Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

- Salix Launches ‘Let’s Talk 2’ IBS Awareness Campaign

- Salix provides update on FDA submission for PLENVU®*